Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

313.89 +1.73 (+0.56%)
Streaming Delayed Price Updated: 3:37 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Buying These Unstoppable Stocks Before 2023 Could Be a Genius Move
These stocks have climbed by double digits this year. 
Via The Motley Fool
Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock
Both stocks are heading for double-digit gains this year. 
Via The Motley Fool
My 3 Best Stocks of 2022 -- and Why I Think They'll Win Again in 2023
The momentum for these high-flying stocks should continue in the new year. 
Via The Motley Fool
Should You Buy Stocks If a Recession Is Coming in 2023? Here's What History Shows.
Stocks usually go down during recessions, but long-term investors can still come out on top. 
Via The Motley Fool
Which Is the Better Buy: Vertex or Invitae?
Is Vertex worth its lofty valuation compared to Invitae? 
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The growth-focused money manager is making moves. 
Via The Motley Fool
3 Growth Stocks With More Potential Than Any Cryptocurrency
If the crypto meltdown has you discouraged, don't give up on stocks. 
Via The Motley Fool
Harpoon Therapeutics Remains Volatile After Promising News
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%. 
Via MarketBeat
More Likely to 5X First: Johnson & Johnson vs. Vertex Pharmaceuticals
This contest isn't even close. 
Via The Motley Fool
Why Merck's $250 Million Investment In Moderna May Have Just Paid Off
Merck opted into Moderna's cancer vaccine. Now, the companies have Phase 2 data. 
Via Investor's Business Daily
3 High-Flying Stocks to Buy and Hold If a Recession Is on the Way
An economic downturn shouldn't hurt these stocks. 
Via The Motley Fool
Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Red-Hot Stocks That Could Continue to Beat the Market
The success these stocks achieved in 2022 could be just the beginning. 
Via The Motley Fool
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 High-Flying Stocks in 2022 That Should Keep Soaring in 2023
These stocks' tailwinds should continue blowing in the new year. 
Via The Motley Fool
Our 7 Top Biotech Stock Picks for 2023
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023. 
Via InvestorPlace
2 Growth Stocks That Could Help Set You Up for Life
Many growth stocks are down, but they're not all out. 
Via The Motley Fool
5 Best Bargain Stocks to Buy Before 2023
It's time to hit the best sale in town, and that involves many top stocks. 
Via The Motley Fool
Entrada Therapeutics Stock Gains On Licensing Pact With Vertex For Form Of Neuromuscular Disorder
 
Via Benzinga
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
The three companies are changing the pharmaceutical industry. 
Via The Motley Fool
Entrada Skyrockets On $250 Million Deal With Vertex In Muscular Dystrophy
Entrada is working on drugs for forms of muscular dystrophy — now, with Vertex's help. 
Via Investor's Business Daily
Is CRISPR Therapeutics a Buy?
A strong cash position could offset some of the near-term risks that come with owning the biotech. 
Via The Motley Fool
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
From Vertex Pharmaceuticals Incorporated
Via Business Wire
2 Unstoppable Growth Stocks to Buy in 2022 and Beyond
These biotech players beat the bear market this year. 
Via The Motley Fool
3 Fierce Stocks That Are Screaming Buys in December
Here are three winners in the making. 
Via The Motley Fool
3 Stocks to Buy Before 2023 That Can Set You Up for Life
These stocks are already good buys right now. 
Via The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
The company has already made plenty of investors happy. 
Via The Motley Fool
Bear Market Bargain Hunting: 3 Top Stocks to Buy Before 2023
These top players are ripe for recovery -- and long-term growth. 
Via The Motley Fool
Is This Biotech Stock a Buy Following a Landmark Approval?
You may not want to be too quick to pull the trigger. 
Via The Motley Fool
3 Stocks to Buy Hand Over Fist in December
These stocks could be big winners. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.